| Therapeutic targeting of oncogenic K‐Ras by a covalent catalytic site inhibitor SM Lim, KD Westover, SB Ficarro, RA Harrison, HG Choi, ME Pacold, ... Angewandte Chemie International Edition 53 (1), 199-204, 2014 | 346 | 2014 |
| A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties K Dooley, RE McConnell, K Xu, ND Lewis, S Haupt, MR Youniss, S Martin, ... Molecular Therapy 29 (5), 1729-1743, 2021 | 170 | 2021 |
| ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance SC Jang, KD Economides, RJ Moniz, CL Sia, N Lewis, C McCoy, T Zi, ... Communications Biology 4 (1), 1-17, 2021 | 87 | 2021 |
| Conformational insight into multi-protein signaling assemblies by hydrogen–deuterium exchange mass spectrometry RA Harrison, JR Engen Current opinion in structural biology 41, 187-193, 2016 | 70 | 2016 |
| KRAS G12C drug development: discrimination between switch II pocket configurations using hydrogen/deuterium-exchange mass spectrometry J Lu, RA Harrison, L Li, M Zeng, S Gondi, D Scott, NS Gray, JR Engen, ... Structure 25 (9), 1442-1448. e3, 2017 | 32 | 2017 |
| Structural dynamics in Ras and related proteins upon nucleotide switching RA Harrison, J Lu, M Carrasco, J Hunter, A Manandhar, S Gondi, ... Journal of molecular biology 428 (23), 4723-4735, 2016 | 30 | 2016 |
| exoSTING: An engineered exosome therapeutic that selectively delivers STING agonist to the tumor resident antigen-presenting cells resulting in improved tumor antigen-specific … SC Jang, RJ Moniz, CL Sia, RA Harrison, D Houde, N Ross, K Xu, ... Cancer Research 79 (13_Supplement), 944-944, 2019 | 13 | 2019 |
| Preparation of therapeutic exosomes using membrane proteins KP Dooley, RA Harrison, RE McConnell, K Xu, DJ Houde, N Ross, ... US Patent 10,195,290, 2019 | 9 | 2019 |
| Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering C Gu, ML Lamb, JW Johannes, MA Sylvester, MS Eisman, RA Harrison, ... Bioorganic & Medicinal Chemistry Letters 26 (19), 4775-4780, 2016 | 6 | 2016 |
| Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes AB Shapiro, J Newman, K Goteti, ME Beaudoin, R Harrison, S Hopkins, ... Antimicrobial agents and chemotherapy 57 (10), 4816-4824, 2013 | 6 | 2013 |
| Preparation of therapeutic exosomes using membrane proteins KP Dooley, RA Harrison, RE McConnell, K Xu, DJ Houde, N Ross, ... US Patent 10,561,740, 2020 | 5 | 2020 |
| Compositions of Engineered Exosomes and Methods of Loading Luminal Exosome Payloads RE McConnell, KP Dooley, RA Harrison, K Xu, DJ Houde, S Haupt, ... US Patent App. 16/194,230, 2019 | 3 | 2019 |
| Preparation of therapeutic exosomes using membrane proteins KP Dooley, RA Harrison, RE McConnell, K Xu, DJ Houde, N Ross, ... US Patent 11,679,164, 2023 | 2 | 2023 |
| Compositions of engineered exosomes and methods of loading luminal exosomes pay-loads RE McConnell, KP Dooley, RA Harrison, K Xu, DJ Houde, S Haupt, ... US Patent App. 16/765,116, 2020 | 2 | 2020 |
| engEx: A novel exosome engineering platform enabling targeted transfer of pharmacological molecules K Dooley, K Xu, S Haupt, N Lewis, R Harrison, S Martin, C McCoy, CL Sia, ... Proceedings of the American Association for Cancer Research Annual Meeting, 2019 | 2 | 2019 |
| Development of a platform for exosome engineering using a novel and selective scaffold protein for surface display K Dooley, K Xu, S Haupt, N Lewis, R Harrison, S Martin, C McCoy, CL Sia, ... J Extracell Vesicles, 2019 | 2 | 2019 |
| Selective Delivery of Exosome-Mediated Sting Agonist to Antigen Presenting Cells Results in Significantly Improved Potency and Reduced Toxicity SC Jang, C Sia, RJ Moniz, J Dey, R Harrison, N Ross, K Xu, K Dooley, ... Proceedings of the 33rd Society for Immunotherapy of Cancer Annual Meeting …, 2018 | 2 | 2018 |
| Therapeutic extracellular vesicle production is substantially increased by inhibition of cellular cholesterol biosynthesis S Martin, R McConnell, R Harrison, SC Jang, CL Sia, S Kamerkar, ... Biotechnology and Bioengineering 120 (9), 2685-2699, 2023 | 1 | 2023 |
| Extracellular vesicles comprising STING-agonist SC Jang, CL Sia, ND Lewis, RA Harrison, RJ Moniz, S Sathyanarayanan, ... US Patent App. 17/040,805, 2021 | 1 | 2021 |
| Selective activation of antigen presenting cells by exoSTING enhances tumor antigen-specific immune response SC Jang, K Zhang, N Lewis, T Zi, J Lim, R Harrison, R Moniz, K Kirwin, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | 1 | 2019 |
